Exchange: NASDAQ·Updated 07:30 PM EDT
News
all
press releases
If You Invested $100 In Axsome Therapeutics Stock 10 Years Ago, You Would Have This Much Today
Axsome Therapeutics (NASDAQ:AXSM) has outperformed the market over the past 10 years by 26.64% on an annualized basis producing an average annual return of 40.19%. Currently, Axsome Therapeutics has a marketread more...
Benzinga
More News
Axsome's Q2 Earnings Meet Estimates, Auvelity Drives Y/Y Revenues
AXSM's Q2 earnings meet estimates, but revenues miss forecasts. Auvelity and other product sales drive year-over-year revenues.
Zacks
AXSM Stock Advances On CEO’s Pipeline Claim: One New Drug Filing Yearly Through 2030
The FDA has already accepted the company’s application seeking the greenlight for AXS-12.
Stocktwits
Axsome (AXSM) Reports Q2 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Axsome (AXSM) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks
Axsome Therapeutics (AXSM) Reports Q2 Loss, Misses Revenue Estimates
Axsome (AXSM) delivered earnings and revenue surprises of 0.00% and -2.74%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Alpha Cognition Inc. (ACOG) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Alpha Cognition Inc. (ACOG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Beats Revenue Estimates
Foghorn Therapeutics (FHTX) delivered earnings and revenue surprises of +56.52% and +98.03%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Countdown to Axsome (AXSM) Q2 Earnings: Wall Street Forecasts for Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Axsome (AXSM), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2026.
Zacks
Gilead Sciences (GILD) Reports Q2 Loss, Beats Revenue Estimates
Gilead (GILD) delivered earnings and revenue surprises of +4.53% and +5.92%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks

Advertisement|Remove ads.